Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 7/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 4/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.40 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9029836 | 0.93 | HDAC1 (0.53) | HDAC1HDAC8HDAC6HDAC3HDAC4 | |
| SCHEMBL9089073 | 0.90 | HDAC1 (0.43) | ALOX5EPHX2HDAC1HDAC8HDAC6 | |
| SCHEMBL9088999 | 0.89 | KDM4E (0.45) | ALOX5 | |
| SCHEMBL8777890 | 0.88 | BRD4 (0.45) | ALOX5EPHX2ACHETNFKCNT1 | |
| SCHEMBL9086492 | 0.88 | BRD4 (0.47) | HDAC1HDAC8HDAC6HDAC3HDAC4 | |
| SCHEMBL8777973 | 0.88 | PTGER4 (0.46) | ALOX5EPHX2HDAC1HDAC8HDAC6 | |
| SCHEMBL8777946 | 0.86 | MAPT (0.41) | ALOX5ACHE | |
| SCHEMBL9090221 | 0.86 | SIRT2 (0.47) | HDAC1HDAC8HDAC6HDAC3HDAC4 | |
| SCHEMBL9088287 | 0.85 | PTGER4 (0.48) | — | |
| SCHEMBL5082657 | 0.85 | PTGER4 (0.48) | HDAC1HDAC8HDAC6HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0651743-B1 | INDOLINYL N-HYDROXYUREA AND N-HYDROXAMIC ACID DERIVATIVES AS LIPOXYGENASE INHIBITORS | PFIZER (US) | 1997-12-17 | — | — | EP | claimed |
| US-5541218-A | Indolinyl N-hydroxyurea and N-hydroxamic acid derivatives as lipoxygenase inhibitors | PFIZER INC. (US) | 1996-07-30 | — | — | US | claimed |
| EP-0651743-A1 | INDOLINYL N-HYDROXYUREA AND N-HYDROXAMIC ACID DERIVATIVES AS LIPOXYGENASE INHIBITORS | PFIZER INC. (US) | 1995-05-10 | — | — | EP | claimed |
| WO-1994002459-A1 | INDOLINYL N-HYDROZYUREA AND N-HYDROXAMIC ACID DERIVATIVES AS LIPOXYGENASE INHIBITORS | PFIZER INC. (US) | 1994-02-03 | — | — | WO | claimed |
| WO-2008021210-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| EP-0651743-B1 | INDOLINYL N-HYDROXYUREA AND N-HYDROXAMIC ACID DERIVATIVES AS LIPOXYGENASE INHIBITORS | PFIZER (US) | 1997-12-17 | — | — | EP | disclosed |
| US-5541218-A | Indolinyl N-hydroxyurea and N-hydroxamic acid derivatives as lipoxygenase inhibitors | PFIZER INC. (US) | 1996-07-30 | — | — | US | disclosed |
| EP-0651743-A1 | INDOLINYL N-HYDROXYUREA AND N-HYDROXAMIC ACID DERIVATIVES AS LIPOXYGENASE INHIBITORS | PFIZER INC. (US) | 1995-05-10 | — | — | EP | disclosed |
| WO-1994002459-A1 | INDOLINYL N-HYDROZYUREA AND N-HYDROXAMIC ACID DERIVATIVES AS LIPOXYGENASE INHIBITORS | PFIZER INC. (US) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | ALOX5 1721/4885EPHX2 2139/4885HDAC1 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.